Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
growth hormone + liraglutide
- Development stage
- Phase 4
- Lead developer
- Novo Nordisk
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
A combination of growth hormone (GH) and liraglutide being investigated for potential effects on metabolism and diabetes management. Growth hormone is a peptide hormone that stimulates growth, cell reproduction, and regeneration, while liraglutide is a GLP-1 receptor agonist used for treating type 2 diabetes and obesity. Research has shown that while liraglutide significantly reduces food intake, improves glucose tolerance, and enhances insulin sensitivity, the addition of growth hormone does not significantly augment these beneficial effects in experimental models.
02
Targets
GLP1R (GLP-1R)GHR (Growth hormone receptor)
Beyond the preview
Go deeper on growth hormone + liraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on growth hormone + liraglutide.